ENA Respiratory Announces FDA IND Clearance for its Prophylactic Intranasal INNA-051 – a First-in-Class Antiviral Innate Immunomodulator
active portfolio companies
Investors and Venture Partners spanning Australia, New Zealand, United States and the United Kingdom